Clinical Trials Logo
  1. Home
  2. Gastric Ulcer
  3. NCT02759224
  4. Details
NCT02759224 Clinical Trial

A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet

Gastric Ulcer Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02759224
Other study ID # BR-LIC-CT-101
Secondary ID
Status Completed
Phase Phase 1
First received April 21, 2016
Last updated February 6, 2017
Start date April 15, 2016
Est. completion date December 29, 2016

Study information
Verified date February 2017
Source Boryung Pharmaceutical Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers

Recruitment information / eligibility
Status Completed
Enrollment 34
Est. completion date December 29, 2016
Est. primary completion date July 1, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy subject, aged 19- 50 years

Exclusion Criteria:

- History of clinically significant and active disease

- History of gastrointestinal disease

- History of clinically significant hypersensitivity to study drug, any other drug

- Laboratory test serum AST or ALT > 1.25 times of upper normal range serum total bilirubin > 1.5 times of upper normal range eGFR < 60 ml/min/1.73m² serological test(HBsAg, HCV Ab, HIV Ag/Ab, Syphilis reagin) positive

- Hypotension or hypertension

- Pregnant or nursing women

- Participation in any other study within 90 days

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• BRI-1501

• Lafutidine

• Irsogladine maleate

Locations
Country Name City State
Korea, Republic of The Catholic University of Korea, Seoul St.Mary's Hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Maximum observed concentration(Cmax) of Lafutidine and Irsogladine maleate 0~36 hour after medication
Primary Area under the plasma drug concentration-time curve(AUClast) of Lafutidine and Irsogladine maleate 0~36 hour after medication
See also
  Status Clinical Trial Phase
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Completed NCT03291418 - To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects Phase 1/Phase 2
Not yet recruiting NCT05526339 - HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients N/A
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Terminated NCT00594854 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec Phase 3
Completed NCT01129011 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Phase 3
Completed NCT00527787 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Phase 3
Recruiting NCT05517408 - Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients. N/A
Recruiting NCT01946633 - Remote-controlled Capsule Endoscopy: a Feasibility Study N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Completed NCT01150162 - Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation Phase 3
Recruiting NCT01037491 - Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets N/A
Completed NCT00961350 - A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Phase 3
Completed NCT00960869 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Phase 3
Completed NCT00595517 - Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer Phase 3
Completed NCT00428701 - An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium Phase 4
Completed NCT01452711 - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer Phase 3
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Completed NCT02761512 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer Phase 3
Recruiting NCT03057171 - A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA